1-4 of 4
Nicola Wallis
Close
Sort by
Journal Articles

A Retrospective Real-World Study of Incident Comorbidities and Complications Among Acute Myeloid Leukemia Patients and Non-Cancer Comparison Patients in the US

Aimee Near, MPH, Shahed Iqbal, PhDMBBS MPH, Huan Huang, PhD, Neil Dhopeshwarkar, PharmD, Kathy Lang, PhD, Nicola Wallis, BSc; MB,ChB; FRCPath; FFPM
Journal: Blood
Blood (2017) 130 (Supplement 1): 3448.
https://doi.org/10.1182/blood.V130.Suppl_1.3448.3448
Published: 2017
Journal Articles

Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors

Jay Lin, PhD MBA, Makenbaeva Dinara, MD MBA, Bilmes Robyn, PharmD, BCOP, Melissa Lingohr-Smith, PhD, Nicola Wallis, MRCPath, FFPM
Journal: Blood
Blood (2015) 126 (23): 876.
https://doi.org/10.1182/blood.V126.23.876.876
Published: 2015
Journal Articles

Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials

Philipp D. le Coutre, MD, Timothy P. Hughes, MD, MBBS, Francois-Xavier Mahon, Dong-Wook Kim, Juan Luis Steegmann, Neil P. Shah, MD, PhD, Nicola Wallis, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 1489.
https://doi.org/10.1182/blood.V122.21.1489.1489
Published: 2013
Journal Articles

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Matthew S. Squires, PhD, Jayne E. Curry, Mark A. Dawson, Mike A. Scott, Kelly Barber, Matthias Reule, Tomoko Smyth, Nicola Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green
Journal: Blood
Blood (2007) 110 (11): 3537.
https://doi.org/10.1182/blood.V110.11.3537.3537
Published: 2007